Announcement of the Results

In 2025, Manners Technology, a world-leading manufacturer of interventional medical devices, officially announced that its new generation of Menchini liver biopsy needle series has passed the most stringent biological material compatibility certification (the complete set of ISO 10993) and has achieved 100% material traceability for key components. This series of products uses aerospace-grade martensitic aging stainless steel, combined with 5-axis ultra-precision laser cutting and nanometer-level electrolytic polishing technology, reducing the roughness (Ra value) of the inner and outer walls of the needle tube to below 0.05 micrometers. Clinical data shows that the complete rate of liver tissue samples obtained using this needle is as high as 99.5%, and the sample deformation rate is reduced by 70%, marking that the manufacturing precision of liver biopsy needles has entered the sub-micron era.

Research and Development Background and Challenges

Although the traditional Menchini needle is relatively safe due to its suction principle, there have been long-standing concerns regarding its materials and manufacturing:

  Risk of material fatigue and fracture: When the needle is repeatedly disinfected or encounters exceptionally tough liver cirrhosis tissues, the needle body may undergo microscopic fatigue and there is a risk of fracture;

  Sample damage caused by rough inner walls: The inner walls of the needle tubes manufactured by the traditional drawing process have microscopic scratches, and when subjected to high-speed negative pressure suction, they will act like a "scraping tool" and scrape the fragile liver tissue, resulting in sample compression (crush artifact), which seriously affects the accuracy of pathological diagnosis;

  Cleaning dead corners and biofilm risks: The complex needle base structure is difficult to thoroughly clean and disinfect, and may become a breeding ground for pathogens. These pain points directly relate to the accuracy of diagnosis and the infection risk for patients.

Core Technological Innovation

The manufacturer carried out three major innovations based on the raw materials' origin and manufacturing limits:

  Material upgrade and full-chain traceability: Instead of using the common 304/316 stainless steel, we select Custom 465 martensitic aging stainless steel. This material maintains excellent corrosion resistance while increasing the yield strength by 50% and having excellent fatigue resistance. What's more, the manufacturer establishes a "digital material passport" for each batch of raw materials, recording their smelting batch, composition analysis, and mechanical performance reports, enabling full traceability from the steel mill to the patient's bedside.

5-axis laser ultra-precision machining: We introduce a 5-axis ultra-fast femtosecond laser cutting machine for the manufacturing of precision optical components. Through computer control, the laser beam can perform "cold processing" on the inclined surface and side holes of the needle tip at any angle, avoiding the thermal deformation and burrs caused by traditional mechanical cutting, and achieving a needle tip edge radius of micrometer level, with the sharpness increased by several times.

  Nanometer-level surface treatment: On the basis of traditional electrolytic polishing, we introduce the magnetic fluid polishing technology. Using intelligent fluids under the action of a magnetic field to form a flexible "polishing mold", it performs molecular-level grinding on the inner wall of the needle tube, making the surface reach an almost mirror-like effect, with the roughness (Ra) reduced from the traditional 0.8 micrometers to below 0.05 micrometers, significantly reducing the fluid friction resistance.

Mechanism of Action

New materials and new technologies work together through the synergistic effects of physical and fluid mechanics:

The high elastic modulus and fatigue limit of high-strength martensitic aging steel ensure that the needle body can resist bending and torsional loads when penetrating the tough Glisson capsule and hard liver, maintaining the straightness of the insertion path and avoiding sampling position deviations caused by needle bending.

The ultra-smooth inner wall significantly reduces the wall shear force of liver tissue samples when they are sucked and moved within the needle tube. According to the principles of fluid mechanics, rough surfaces will generate turbulence and vortices, damaging the tissue; while the mirror-like inner wall maintains a laminar flow state, like an "air cushion", protecting the sample from complete disruption as it passes through.

The ultra-sharp laser cutting edge can quickly cut liver tissue with the minimum puncture force (usually less than 5N), reducing the compression and tearing of surrounding tissues around the needle path, and lowering the risk of postoperative bleeding and hematoma. The sharp edge also ensures a clean cutting surface, facilitating the observation of cell morphology by pathologists.

Efficacy Verification

This series of products has passed the enhanced test of ASTM F899 (the standard for surgical stainless steel) and has completed over 1,500 blind-controlled clinical trials at three top liver disease centers worldwide.

  Mechanical testing of materials: A synthetic model simulating F4 grade liver cirrhosis (the hardest) was created. After 100 consecutive punctures with the new needle, the sharpness of the needle tip decreased by less than 10%, while the traditional needle showed a decline of more than 40%.

  Sample quality pathological assessment: An independent pathology expert panel conducted blind evaluation of the biopsy samples. The samples obtained with the new needle had a complete tissue strip rate (length > 1.5 cm and without breakage) of 99.5%, and a diagnostic sufficiency rate (including at least 6 complete venous channels) of 98.8%, significantly higher than 92% and 90% of the control group.

  Postoperative complication monitoring: The incidence of major complications (requiring intervention, such as bleeding and bile leakage) decreased from 0.5% reported in the literature to 0.1%; the average VAS score for pain at the puncture site reported by patients decreased by 1.5 points.

Research and Development Strategy and Philosophy

The R & D strategy of Manners Technology is "returning to the physical essence and pursuing the ultimate precision". They believe that for medical devices that enter the human body, their biological safety is first based on physical safety. They collaborated with the National Materials Science Laboratory and established the "Medical Metal Materials Database", conducting long-term fatigue performance tests on dozens of alloys in simulated body fluid environments. Their core concept is "eliminating uncertainty to zero", through fundamental innovations in materials science and extreme control of manufacturing processes, compressing the fluctuation range of product performance to the minimum, ensuring that every biopsy needle produced is consistent and of outstanding performance.

Future Outlook

In the future, material innovation will move towards "biological functionalization" and "intelligence". Manufacturers are currently testing "self-lubricating antibacterial coatings" in the laboratory: coating the inner wall of the syringe with a hydrophilic gel coating that activates upon contact with blood. This not only further reduces the suction resistance but also slowly releases antibacterial ions. The more advanced exploration is "biodegradable alloy needles", where the part of the needle tip left in the needle channel can safely degrade within several weeks and promote local tissue repair. Another direction is to integrate "micro-fiber sensing arrays" into the needle wall, providing real-time feedback on the tissue impedance spectrum during the puncture process, and preliminarily determining the nature of the tissue (such as the degree of fatty degeneration, fibrosis grading), achieving "diagnostic puncture". The manufacturers' goal is to transform the biopsy needle from a "tissue acquisition tool" into an "in vivo real-time diagnostic platform".